Drug Trial Radar · NCT01808573
A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
621
Actual
Start
Mar 29, 2013
Primary completion
Sep 28, 2018
Study completion Dec 9, 2019
Sponsor
- Lead sponsor
- Puma Biotechnology, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, multi-center, multinational, open-label, active-controlled, parallel design study of the combination of neratinib plus capecitabine versus the combination of lapatinib plus capecitabine in HER2+ MBC patients who have received two or more prior HER2 directed regimens in the metastatic setting.
Conditions
- HER2+ Metastatic Breast Cancer (MBC)
Interventions
neratinibDrug
capecitabineDrug
lapatinibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Centrally Assessed Progression Free SurvivalTime frame: From randomization date to recurrence, progression or death, assessed up to 38 months. The result is based on primary analysis data cut.
- Overall SurvivalTime frame: From randomization date to death, assessed up to 59 months.The result is based on primary analysis data cut.
Locations
252 sites in 28 countries. Site status is shown where the registry gives one.
Ironwood Cancer and Research Centers
Chandler, Arizona
Ironwood Cancer and Research Centers
Gilbert, Arizona
Ironwood Cancer and Research Centers
Mesa, Arizona
Ironwood Cancer and Research Centers
Scottsdale, Arizona
UCLA Hematology Oncology
Alhambra, California
CBCC Global Research, Inc. at Comprehensive Blood and Caner Center
Bakersfield, California
Compassionate Cancer Care Medical Group Inc.
Fountain Valley, California
St. Jude Heritage Medical Group
Fullerton, California
St. Jude Heritage Medical Group
Fullerton, California
Marin Cancer Care, Inc.
Greenbrae, California
UCLA Hematology Oncology
Irvine, California
University of California San Diego Medical Center
La Jolla, California
University of California San Diego Moores Cancer Center
La Jolla, California
Breastlink Medical Group, Inc.
Orange, California
UCLA Hematology Oncology
Pasadena, California
UCLA Hematology Oncology
Porter Ranch, California
Emad Ibrahim, MD
Redlands, California
Cancer Care Associates Medical Group, Inc
Redondo Beach, California
Compassionate Cancer Care Medical Group
Riverside, California
University of California San Diego Medical Center - Hillcrest
San Diego, California
Sharp Memorial Hospital
San Diego, California
Breastlink Medical Group, Inc.
Santa Ana, California
Cancer Center of Santa Barbara Sansum Clinic
Santa Barbara, California
Central Coast Medical Oncology
Santa Maria, California
UCLA Hematology Oncology
Santa Monica, California
Cancer Center of Santa Barbara
Solvang, California
UCLA Healthcare Santa Clarita Oncology
Valencia, California
UCLA Hematology/Oncology
Westlake Village, California
Sibley Memorial Hospital
Washington D.C., District of Columbia
Broward Medical Oncology Office
Plantation, Florida
Florida Cancer Research Institute
Plantation, Florida
Emory University Hospital Midtown
Atlanta, Georgia
Emory Clinic
Atlanta, Georgia
Emory University Winship Cancer Institute
Atlanta, Georgia
OnCare Hawaii
Honolulu, Hawaii
Queen's Medical Center
Honolulu, Hawaii
Straub Clinic and Hospital
Honolulu, Hawaii
University of Hawaii Cancer Center
Honolulu, Hawaii
Resurrection Medical Group
Chicago, Illinois
North Shore Oncology-Hematology Associates, Ltd.
Crystal Lake, Illinois
Showing 40 of 252 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.